Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: A French multi-centre collaborative study

Virology Journal

Volumn 10, Issue , 2013, Pages

  Thibault, Vincent ^a   Gaudy Graffin, Catherine ^b   Colson, Philippe ^c   Gozlan, Joël ^d   Schnepf, Nathalie ^e   Trimoulet, Pascale ^f   Pallier, Coralie ^g   Saune, Karine ^h   Branger, Michel ⁱ   Coste, Marianne ^j   Thoraval, Francoise Roudot ^k  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c TIMONE HOSPITAL   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e HÔPITAL LARIBOISIÈRE   (France)

^f HÔPITAL PELLEGRIN   (France)

^g Section of Radiology   (France)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁱ BICHAT HOSPITAL   (France)

^j NANTES UNIVERSITY HOSPITAL   (France)

^k HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

Genotype; HBsAg variants; HBV HIV co infection; Liver lesions; Resistance mutations

Indexed keywords

ADEFOVIR; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; DRUG EXPOSURE; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; RISK FACTOR; UNIVERSITY HOSPITAL; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIBODIES, VIRAL; COINFECTION; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VIRAL LOAD;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84874930744     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-87     Document Type: Article

References (39)

1. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD, Aids 2005 19 593 601 10.1097/01.aids. 0000163936.99401.fe 15802978 (Pubitemid 40543982)
2. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, Mauss S, Rockstroh J, Aids 2008 22 1399 1410 10.1097/QAD.0b013e3282f8b46f 18614862
3. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, Herson S, Poynard T, Opolon P, Ann Intern Med 1996 125 705 712 8929003 (Pubitemid 126450357)
4. HIV and viral hepatitis coinfections: advances and challenges. Lacombe K, Rockstroh J, Gut 2012 61 Suppl 1 47 58 10.1136/gutjnl-2012-302062 22504919
5. Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status. Halfon P, Bourliere M, Pol S, Benhamou Y, Ouzan D, Rotily M, Khiri H, Renou C, Penaranda G, Saadoun D, J Viral Hepat 2006 13 329 335 10.1111/j.1365-2893.2005.00692.x 16637864
6. Distribution of hepatitis B virus genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications. Perez-Olmeda M, Nunez M, Garcia-Samaniego J, Rios P, Gonzalez-Lahoz J, Soriano V, AIDS Res Hum Retroviruses 2003 19 657 659 10.1089/088922203322280874 13678467 (Pubitemid 37047090)
7. Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999-2004. Trimoulet P, Boutonnet M, Winnock M, Faure M, Loko MA, De Ledinghen V, Bernard PH, Castera L, Foucher J, Dupon M, Gastroenterol Clin Biol 2007 31 1088 1094 10.1016/S0399-8320(07)78341-0 18176363
8. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. Zoulim F, Poynard T, Degos F, Slama A, El Hasnaoui A, Blin P, Mercier F, Deny P, Landais P, Parvaz P, Trepo C, J Viral Hepat 2006 13 278 288 10.1111/j.1365-2893.2005.00712.x 16611195
9. Hepatitis B vaccination and French Society ten years after the suspension of the vaccination campaign: how should we raise infant immunization coverage rates? Balinska MA, J Clin Virol 2009 46 202 205 10.1016/j.jcv.2009.07.024 19716764
10. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Larsen C, Pialoux G, Salmon D, Antona D, Le Strat Y, Piroth L, Pol S, Rosenthal E, Neau D, Semaille C, Delarocque Astagneau E, Euro Surveill 2008 13 1 4
11. Yeni P, French Experts group's recommendations for medical management of HIV infection highlights and recommendations 2006 [ http://www.sante.gouv.fr/ IMG/pdf/rapport-experts-angl-2006.pdf ] 23345311
12. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, Gibbs CS, Parvaz P, Werle B, Trepo C, Zoulim F, J Hepatol 2003 39 1085 1089 10.1016/j.jhep.2003.09.022 14642631 (Pubitemid 37523785)
13. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Tamura K, Dudley J, Nei M, Kumar S, Mol Biol Evol 2007 24 1596 1599 10.1093/molbev/msm092 17488738 (Pubitemid 47236692)
14. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. Bottero J, Lacombe K, Guechot J, Serfaty L, Miailhes P, Bonnard P, Wendum D, Molina JM, Lascoux-Combe C, Girard PM, J Hepatol 2009 50 1074 1083 10.1016/j.jhep.2009.01.022 19398234
15. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, Reiss P, Thiebaut R, Weiland O, Yazdanpanah Y, Zeuzem S, J Hepatol 2005 42 615 624 10.1016/j.jhep.2005.03.003 15916745
16. EASL Clinical Practice Guidelines: management of chronic hepatitis B. European Association For The Study Of The L, J Hepatol 2009 50 227 242 10.1016/j.jhep.2008.10.001 19054588
17. Chronic hepatitis B: update 2009. Lok AS, McMahon BJ, Hepatology 2009 50 661 662 10.1002/hep.23190 19714720
18. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, Puoti M, Soriano V, Tural C, HIV Med 2008 9 82 88 10.1111/j.1468-1293. 2007.00535.x 18257771 (Pubitemid 351228130)
19. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. Hoffmann CJ, Seaberg EC, Young S, Witt MD, D'Acunto K, Phair J, Thio CL, Aids 2009 23 1881 1889 10.1097/QAD.0b013e32832e463a 19550291
20. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte A, Flisiak R, Lundgren J, J Antimicrob Chemother 2010 65 548 555 10.1093/jac/dkp479 20051475
21. Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20years. Chun HM, Fieberg AM, Hullsiek KH, Lifson AR, Crum-Cianflone NF, Weintrob AC, Ganesan A, Barthel RV, Bradley WP, Agan BK, Landrum ML, Clin Infect Dis 2010 50 426 436 10.1086/649885 20047484
22. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. Lacombe K, Massari V, Girard PM, Serfaty L, Gozlan J, Pialoux G, Mialhes P, Molina JM, Lascoux-Combe C, Wendum D, Aids 2006 20 419 427 10.1097/01.aids.0000200537.86984.0e 16439876
23. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. Zarski JP, Marcellin P, Leroy V, Trepo C, Samuel D, Ganne-Carrie N, Barange K, Canva V, Doffoel M, Cales P, J Hepatol 2006 45 355 360 10.1016/j.jhep.2006.03.007 16750585 (Pubitemid 44160628)
24. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R, J Gen Virol 2000 81 67 74 10640543 (Pubitemid 30047907)
25. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Kato H, Orito E, Gish RG, Bzowej N, Newsom M, Sugauchi F, Suzuki S, Ueda R, Miyakawa Y, Mizokami M, Hepatology 2002 35 922 929 10.1053/jhep.2002.32096 11915040 (Pubitemid 34258388)
26. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T, Hepatology 1999 30 1302 1306 10.1002/hep.510300525 10534354 (Pubitemid 29510871)
27. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. Delaney WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S, J Virol 2003 77 11833 11841 10.1128/JVI.77.21.11833-11841.2003 14557667 (Pubitemid 37271680)
28. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Miailhes P, Trabaud MA, Pradat P, Lebouche B, Chevallier M, Chevallier P, Zoulim F, Trepo C, Clin Infect Dis 2007 45 624 632 10.1086/520752 17682999 (Pubitemid 47328645)
29. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Huppe D, Stein K, Trojan J, Hepatology 2010 51 73 80 10.1002/hep.23246 19998272
30. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Warner N, Locarnini S, Hepatology 2008 48 88 98 10.1002/hep.22295 18537180 (Pubitemid 351975534)
31. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H, Antimicrob Agents Chemother 2006 50 3867 3874 10.1128/AAC.00239-06 16982790 (Pubitemid 44684905)
32. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. de Vries-Sluijs TE, Reijnders JG, Hansen BE, Zaaijer HL, Prins JM, Pas SD, Schutten M, Hoepelman AI, Richter C, Mulder JW, Gastroenterology 2010 139 1934 1941 10.1053/j.gastro. 2010.08.045 20801123
33. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Gastroenterology 2011 140 132 143 10.1053/j.gastro.2010.10.011 20955704
34. Substitution rate of the hepatitis B virus surface gene. Zaaijer HL, Bouter S, Boot HJ, J Viral Hepat 2008 15 239 245 10.1111/j.1365-2893.2007.00938. x 18086177 (Pubitemid 351326905)
35. Viral and clinical factors associated with surface gene variants among hepatitis B virus carriers. Roque-Afonso AM, Ferey MP, Ly TD, Graube A, Costa-Faria L, Samuel D, Dussaix E, Antivir Ther 2007 12 1255 1263 18240865
36. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. Sheldon J, Ramos B, Garcia-Samaniego J, Rios P, Bartholomeusz A, Romero M, Locarnini S, Zoulim F, Soriano V, J Acquir Immune Defic Syndr 2007 46 279 282 10.1097/QAI.0b013e318154bd89 18167643 (Pubitemid 350287353)
37. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. Landrum ML, Hullsiek KH, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, O'Connell RJ, Fieberg A, Chun HM, Marconi VC, Aids 2010 24 545 555 10.1097/QAD.0b013e32832cd99e 19487908
38. Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy? Jain MK, Opio CK, Osuagwu CC, Pillai R, Keiser P, Lee WM, Clin Infect Dis 2007 44 996 1000 10.1086/512367 17342656 (Pubitemid 46452069)
39. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Chen CJ, Yang HI, Iloeje UH, Hepatology 2009 49 72 84 10.1002/hep.22884 19399801